Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults
NCT07225413, Not applicable, Completed, Jacksonville State University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults | ClinicalTrials.gov |
| NCT number | NCT07225413 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 27 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Jacksonville State University | ClinicalTrials.gov |
| Conditions | Healthy Volunteers | ClinicalTrials.gov |
| Interventions | Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules | ClinicalTrials.gov |
| First posted | 2025-11-06 | ClinicalTrials.gov |
| Last updated | 2025-11-06 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Load volume (kg) during 3rd set to failure at 60% 1RM | Day 7 of each 7-day period | Participants performed bench presses and leg presses at 60% of their familiarization 1RM. On the 3rd set, they lifted to volitional failure; load volume was calculated as load (kg) × repetitions. Values after administration of low- and high-dose Rhodiola rosea were compared with those of the placebo and control groups. | ClinicalTrials.gov |
| Primary | Wingate anaerobic test peak power | Day 7 of each 7-day period | Participants completed a 30-s Wingate test on a cycle ergometer; peak power (W) was recorded. Values after low- and high-dose Rhodiola rosea were compared with those of the placebo and control to assess the effects on anaerobic performance. | ClinicalTrials.gov |
| Primary | Executive function (Stroop Color-Word Test) | Day 7 of each 7-day period | The paper-and-pencil Stroop Color-Word Test is administered (Word, Color, and Color-Word, 45 s each). The total number of correct responses across the three sections is recorded. Higher scores indicate better executive control. | ClinicalTrials.gov |
| Secondary | Readiness to Perform (Visual Analog Scale, 0-100 mm) | Day 7 of each 7-day period | Participants rated six items before testing on a 0-100 mm line anchored 0 = strongly disagree (worse) and 100 = strongly agree (better): (1) I slept well last night; (2) I am looking forward to today's workout; (3) I am optimistic about my future performance; (4) I feel vigorous and energetic; (5) My appetite is great; (6) I have little muscle soreness. Scores were recorded in millimeters; higher values indicate better readiness (greater agreement). | ClinicalTrials.gov |
| Secondary | Rating of Perceived Exertion (RPE) after resistance exercise | Day 7 of each 7-day period | RPE is recorded 1 minute after the 3rd set of bench press and leg press using the Borg 6-20 scale. Higher values indicate greater perceived exertion. | ClinicalTrials.gov |
| Secondary | Resting Heart Rate | Day 7 of each 7-day period | Seated/resting heart rate measured before testing. Unit: beats per minute (bpm). Higher values indicate higher HR. | ClinicalTrials.gov |
| Secondary | 1-Minute Post-Exercise Heart Rate | Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate). | Heart rate was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: beats per minute (bpm). Higher values indicate higher HR. | ClinicalTrials.gov |
| Secondary | Resting Systolic Blood Pressure | Day 7 of each 7 days (pre-test). | Seated/resting SBP measured before testing using an automated oscillometric device per manufacturer guidelines. Unit: mmHg. Higher values indicate higher SBP. | ClinicalTrials.gov |
| Secondary | Resting Diastolic Blood Pressure | Day 7 of each 7 days (pre-test). | Seated/resting DBP measured before testing using an automated oscillometric device per manufacturer guidelines. Unit: mmHg. Higher values indicate higher DBP. | ClinicalTrials.gov |
| Secondary | 1-Minute Post-Exercise Systolic Blood Pressure | Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate). | SBP was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: mmHg. Higher values indicate higher SBP. | ClinicalTrials.gov |
| Secondary | 1-Minute Post-Exercise Diastolic Blood Pressure | Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate). | DBP was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: mmHg. Higher values indicate higher DBP. | ClinicalTrials.gov |
| Secondary | Adverse Events / Side-Effects-Frequency (0-5 Likert) | Day 7 of each 7 days (post-condition). | Participants completed a side-effects questionnaire rating how often each symptom occurred using a 6-point scale (0 = none; 1 = minimal \[1-2/week\]; 2 = slight \[3-4/week\]; 3 = occasional \[5-6/week\]; 4 = frequent \[7-8/week\]; 5 = severe \[≥9/week\]). Symptoms queried: dizziness, headache, fast/racing heart rate, heart skipping/palpitations, shortness of breath, nervousness, blurred vision, and "any other unusual/adverse effects." Scores range 0-5 per item; higher = worse (more frequent). Each item was analyzed separately; an optional composite frequency score (item mean) was also recorded. | ClinicalTrials.gov |
| Secondary | Adverse Events / Side-Effects-Severity (0-5 Likert) | Day 7 of each 7 days (post-condition). | Description: Using the same questionnaire, participants rated how severe each symptom was on a 6-point scale (0 = none; 1 = minimal; 2 = slight; 3 = moderate; 4 = severe; 5 = very severe). Symptoms queried: dizziness, headache, fast/racing heart rate, heart skipping/palpitations, shortness of breath, nervousness, blurred vision, and "any other unusual/adverse effects." Scores range 0-5 per item; higher = worse (more severe). Each item was analyzed separately; an optional composite severity score (item mean) was also recorded. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)